Gilead's latest chronic hepatitis C drug "Ji San generation" Vosway is listed in China, within 100,000 to fix the hepatitis C

June 30, Gilead Sciences announced that the daily preparation of the monophosphate vivo tablets (commodity name: Wassway, Sophosbuvir 400mg/Vipatavir 100mg/Vosiliwe 100mg, SOF/VEL/VOX) was officially launched in Chinaphosphate vivin sandis approved by the State Drug AdministrationAdministrationBureau at the end of 2019 for the treatment of adults who have previously received ainfection with chronic hepatitis C virus (HCV)infected with an adult with direct antiviral drug (DAA) program, no cirrhosis or associated cirrhosis of the liverhepatitis Cis the fourth most common infectious disease in China, caused by HCV infection, is the second most common cause of liver cancer in China, about 10 million people infected with hepatitis CHepatitis C treatment can be divided into PR treatment options (injection of polyglycol interferon joint ribavirin), DAA (new direct antiviral drugs of hepatitis C) joint PR program, DAA all oral programbefore DAA therapy entered the country in 2017, the domestic standard treatment regimen was PR treatment, but the treatment program had high side effects, poor patient tolerance, and a cure rate of 50%-70%The DAA-based antiviral program, which has a short course of treatment, safety and better tolerance, achieves more than 90% hepatitis C cure rateAlthough the emergence of DAA drugs greatly increased the cure rate of hepatitis C, but due to the complexity of the disease and different characteristics of patients, the clinical process of DAA drugs still have a failure rate of about 5%For this part of the patient, the choice of treatment is extremely limited when re-treatment"The launch of the sophos vivo tablet will fill the last gap in the cure for chronic hepatitis C." Wei Lai, director of the hepatobiliary pancreas center at Tsinghua Changyu Hospital in Beijing, affiliated with Tsinghua University, said in an interview with the media, including Interface NewsAccording to two Phase III clinical studies called POLARIS-1 and POLARIS-4, the results show that the overall cure rate of patients with Failed DAA treatment was 97%, of which the cure rate was as high as 99% and 100% for patients with the largest proportion of gene 1b and Type 2 HCV in Chinahepatitis C virus mainly has 6 genotypes and a variety of subtypes, according to the Chinese Medical Association hepatology credit association, the Chinese Medical Association infection credit association 2019 revised "hepatitis C prevention and control guidelines", HCV 1b and 2a genotypes are more common in China, of which 1b-based, followed by type 2 and 32019, three DAA drugs, such as Saphosbuwe/Vipatavir tablets, Lydy Pawe/Sophosbuwe tablets and Elbawe/Grarevir tablets, were included in medics for the first time in the process of adjusting the national health insurance catalog, on an average of 85 percentThe process of reducing prices into health insurance has also greatly improved the public'sscreeningthe enthusiasm of hepatitis C and patient drug accessibility, Professor Wei said, as health insurance hits the ground, the number of patients treated with DAA increases, as the number of people who fail to treat them increases, and demand for drugs increases"It is very much expected that (saphosphovivootablets) will be able to enter Health Insurance as a rescue treatment, and that in the future, Medicare will be able to reimburse patients with previous (DAA) treatments for the use of sorphosvist tablets." Professor Wei lai said that if access to health care, drug prices will also fall furtherAt present, the price of the course of treatment of phosphorus vissops is 98994 yuanNetwork Source: Network